TOBIRA THERAPTC (TBRA)
(Delayed Data from NSDQ)
$42.09 USD
+0.27 (0.65%)
Updated Oct 31, 2016 03:59 PM ET
After-Market: $42.25 (%) 6:00 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[TBRA]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Industry: Medical - Biomedical and Genetics
NASH Update: Gilead Plans Phase 3 with Selonsertib; CENTAUR Subgroup Analyses Shows Greater Benefit in Advanced Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Industry: Medical - Biomedical and Genetics
Allergan Acquires Tobira for ~$550M Upfront and $1.7B All-in With CVRs
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Industry: Medical - Biomedical and Genetics
CENTAUR Is a NASH Breakthrough; Providing CVC a Clear Path to Phase 3 in 1H17; Raise PT to $31
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 50.00
Industry: Medical - Biomedical and Genetics
CENTAUR Establishes CVC''s Potent Anti-fibrotic Effect; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Industry: Medical - Biomedical and Genetics
Results from Multiple Pre-clinical Studies of CVC Published in PLOS ONE and Hepatology
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Industry: Medical - Biomedical and Genetics
1Q16 Recap: Strong Execution Marked by Positive Data and Deal Flow; Awaiting Key CENTAUR Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 25.00
Industry: Medical - Biomedical and Genetics
Positive Interim ORION Data Points to Metabolic Benefits with CVC; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Industry: Medical - Biomedical and Genetics
Targeting the Inflammatory Cascade and Fibrogenesis in NASH; Initiate at Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 75.00
|
|